Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa

Lancet

Volumn 355, Issue 9221, 2000, Pages 2095-2100

  Wood, Evan ^a,b   Braitstein, Paula ^a,b   Montaner, Julio S G ^a,b   Schechter, Martin T ^a,b   Tyndall, Mark W ^a,b   O'Shaughnessy, Michael V ^a,b   Hogg, Robert S ^a,b,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; ARTICLE; COST BENEFIT ANALYSIS; DEMOGRAPHY; DEVELOPING COUNTRY; DRUG COST; EPIDEMIC; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POPULATION MODEL; PRIORITY JOURNAL;

EID: 0034679283     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02375-8     Document Type: Article

References (38)

1. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998; 12: 279-84.
2. Phair JP. Determinants of the natural history of human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179 (Suppl 2): S384-86.
3. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-54.
4. IAS position paper on prevention of HIV 1 mother-to-child transmission. International Aids Society. AIDS 1999; 13: 5-9.
5. Dabis F, Msellati P, Meda N, et al, for the DITRAME Study Group. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353: 786-92.
6. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353: 781-85.
7. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.
8. Saba J. Current status of PETRA study: 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, Quebec: September 2, 1999.
9. Hogg RS, Weber AE, Craib KJ, et al. One world, one hope: the cost of providing antiretroviral therapy to all nations. AIDS 1998; 12: 2203-09.
10. Stover J, Way P. Projecting the impact of AIDS on mortality. AIDS 1998; 12: S29-39.
11. Perinatal HIV Intervention Research in Developing Countries Workshop participants. Science, ethics, and the future of research into maternal infant transmission of HIV-1. Lancet 1999; 353: 832-35.
12. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283: 1175-82.
13. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: two potential futures. AIDS 2000; 14: 1229-36.
14. US Bureau of the Census, Population Division. International Database. Washington, DC, 1999.
15. US Bureau of the Census. World population profile: 1998, report WP/98. Washington DC: US Government Printing Office, 1999.
16. United Nations Secretariat. The demographic impact of HIV/AIDS: report on the technical meeting, New York, 10 November 1998. Geneva: Population Division Department of Economic and Social Affairs, 1999.
17. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14: 117-21.
18. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-29.
19. Campa AM, Shor-Posner G, Baum MK. HIVNET nevirapine trials. Lancet 1999; 354: 1817.
20. Marseille E, Kahn JG, Guay L, Gowler MG, Jackson JB. HIVNET nevirapine trials. Lancet 1999; 354: 1817.
21. UNAIDS Press Release. New public/private sector effort initiated to accelerate access to HIV/AIDS care and treatment in devloping countries. May 11, 2000.
22. World Development Indicators 2000. Washington, DC: World Bank, 2000.
23. Hogg RS, Heath KV, Strathdee SA, Montaner JS, O'Shaughnessy MV, Schechter MT. HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials. AIDS 1996; 10: 889-94.
24. Marseille E, Kahn JG, Saba J. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 1998; 12: 939-48.
25. Marseille E, Kahn JG, Mmiro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999; 354: 803-09.
26. Soderlund N, Zwi K, Kinghorn A, Gray G. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. BMJ 1999; 318: 1650-56.
27. McIntyre JA, Gray GE. Acceptability of voluntary HIV testing by pregnant women in developing countries: an international survey. Int Conf AIDS 1998; 12: 406 (abstr 23322).
28. Gilson L, Mkanje R, Grosskurth H, et al. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Lancet 1997; 350: 1805-09.
29. Anon. Doctors slam minister for blaming deaths on drug. Sunday Times of South Africa 2000; April 9.
30. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-92.
31. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479-86.
32. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates: Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-74.
33. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287: 650-54.
34. Wood E, Low-Beer S, Bartholomew K, et al. Modern antiretroviral therapy improves life expectancy of gay and bisexual males in Vancouver's west end. Can J Public Health 2000; 91: 125-28.
35. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717-20.
36. UNAIDS and World Health Organization. Guidance modules on antiretroviral treatments-module 2: introducing antiretroviral treatments into health systems: economic considerations. Geneva: UNAIDS/WHO, 1998: 40.
37. Gallant JE. Strategies for long-term success in the treatment of HIV infection. JAMA 2000; 283: 1329-34.
38. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283: 1167-74.